CCCC Deferred Long Term Liab vs Net Debt Analysis

CCCC Stock

USD 4.05 0.10 2.41%

C4 Therapeutics financial indicator trend analysis is way more than just evaluating C4 Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether C4 Therapeutics is a good investment. Please check the relationship between C4 Therapeutics Deferred Long Term Liab and its Net Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.

Deferred Long Term Liab vs Net Debt

Deferred Long Term Liab vs Net Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of C4 Therapeutics Deferred Long Term Liab account and Net Debt. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between C4 Therapeutics' Deferred Long Term Liab and Net Debt is -0.19. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Net Debt in the same time period over historical financial statements of C4 Therapeutics, assuming nothing else is changed. The correlation between historical values of C4 Therapeutics' Deferred Long Term Liab and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of C4 Therapeutics are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Deferred Long Term Liab i.e., C4 Therapeutics' Deferred Long Term Liab and Net Debt go up and down completely randomly.

Correlation Coefficient

-0.19

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most indicators from C4 Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into C4 Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.At present, C4 Therapeutics' Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 2.13, whereas Selling General Administrative is forecasted to decline to about 27.4 M.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	2.9M	7.6M	7.7M	4.4M
Interest Income	387K	3.6M	8.6M	9.0M

Depreciation And Amortization Interest Income

C4 Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.79	0.9	0.95	1.0	-0.91	0.99	0.67	0.78	-0.16	-0.78	0.44	0.57	0.86	0.73	0.74	0.96	-0.81	0.84	-0.98	0.7	0.93	0.96	-0.98	1.0	0.7
Short Long Term Debt Total	0.79		0.93	0.76	0.79	-0.91	0.81	0.98	0.55	0.26	-0.89	0.02	0.26	0.83	0.81	0.96	0.76	-0.7	0.77	-0.77	0.99	0.6	0.89	-0.76	0.79	0.99
Other Current Liab	0.9	0.93		0.93	0.9	-0.97	0.92	0.87	0.62	-0.05	-0.92	0.36	0.54	0.85	0.73	0.91	0.89	-0.89	0.94	-0.91	0.89	0.76	0.97	-0.89	0.89	0.89
Total Current Liabilities	0.95	0.76	0.93		0.95	-0.91	0.94	0.64	0.76	-0.28	-0.8	0.62	0.67	0.82	0.69	0.71	0.96	-0.94	0.95	-0.97	0.67	0.91	0.94	-0.95	0.95	0.67
Total Stockholder Equity	1.0	0.79	0.9	0.95		-0.9	0.99	0.67	0.76	-0.19	-0.78	0.46	0.6	0.84	0.7	0.74	0.96	-0.82	0.85	-0.99	0.69	0.92	0.97	-0.98	1.0	0.7
Other Liab	-0.91	-0.91	-0.97	-0.91	-0.9		-0.91	-0.85	-0.64	0.02	0.96	-0.27	-0.48	-0.88	-0.76	-0.89	-0.87	0.82	-0.88	0.91	-0.87	-0.78	-0.95	0.92	-0.9	-0.87
Net Tangible Assets	0.99	0.81	0.92	0.94	0.99	-0.91		0.71	0.68	-0.2	-0.8	0.42	0.62	0.84	0.66	0.79	0.95	-0.82	0.85	-0.98	0.73	0.89	0.98	-0.97	0.99	0.73
Property Plant And Equipment Net	0.67	0.98	0.87	0.64	0.67	-0.85	0.71		0.4	0.35	-0.87	-0.12	0.17	0.77	0.74	0.97	0.63	-0.6	0.69	-0.65	1.0	0.46	0.81	-0.65	0.66	1.0
Current Deferred Revenue	0.78	0.55	0.62	0.76	0.76	-0.64	0.68	0.4		0.03	-0.44	0.48	0.25	0.7	0.85	0.35	0.78	-0.68	0.64	-0.72	0.41	0.83	0.65	-0.7	0.77	0.43
Net Debt	-0.16	0.26	-0.05	-0.28	-0.19	0.02	-0.2	0.35	0.03		0.04	-0.74	-0.86	0.26	0.44	0.2	-0.31	0.35	-0.29	0.3	0.31	-0.15	-0.12	0.31	-0.19	0.33
Retained Earnings	-0.78	-0.89	-0.92	-0.8	-0.78	0.96	-0.8	-0.87	-0.44	0.04		-0.15	-0.49	-0.74	-0.62	-0.9	-0.76	0.75	-0.83	0.82	-0.88	-0.59	-0.88	0.83	-0.77	-0.88
Accounts Payable	0.44	0.02	0.36	0.62	0.46	-0.27	0.42	-0.12	0.48	-0.74	-0.15		0.75	0.19	0.09	-0.02	0.57	-0.72	0.63	-0.51	-0.09	0.56	0.35	-0.48	0.46	-0.09
Cash	0.57	0.26	0.54	0.67	0.6	-0.48	0.62	0.17	0.25	-0.86	-0.49	0.75		0.17	-0.03	0.29	0.7	-0.71	0.7	-0.7	0.2	0.46	0.59	-0.7	0.6	0.18
Non Current Assets Total	0.86	0.83	0.85	0.82	0.84	-0.88	0.84	0.77	0.7	0.26	-0.74	0.19	0.17		0.85	0.81	0.73	-0.68	0.73	-0.79	0.78	0.87	0.85	-0.77	0.84	0.8
Non Currrent Assets Other	0.73	0.81	0.73	0.69	0.7	-0.76	0.66	0.74	0.85	0.44	-0.62	0.09	-0.03	0.85		0.65	0.68	-0.6	0.63	-0.64	0.73	0.7	0.7	-0.63	0.71	0.76
Other Assets	0.74	0.96	0.91	0.71	0.74	-0.89	0.79	0.97	0.35	0.2	-0.9	-0.02	0.29	0.81	0.65		0.67	-0.65	0.74	-0.73	0.97	0.54	0.87	-0.72	0.73	0.97
Cash And Short Term Investments	0.96	0.76	0.89	0.96	0.96	-0.87	0.95	0.63	0.78	-0.31	-0.76	0.57	0.7	0.73	0.68	0.67		-0.9	0.9	-0.98	0.66	0.85	0.94	-0.97	0.97	0.66
Net Receivables	-0.81	-0.7	-0.89	-0.94	-0.82	0.82	-0.82	-0.6	-0.68	0.35	0.75	-0.72	-0.71	-0.68	-0.6	-0.65	-0.9		-0.99	0.86	-0.63	-0.75	-0.84	0.84	-0.82	-0.62
Common Stock Shares Outstanding	0.84	0.77	0.94	0.95	0.85	-0.88	0.85	0.69	0.64	-0.29	-0.83	0.63	0.7	0.73	0.63	0.74	0.9	-0.99		-0.89	0.71	0.75	0.88	-0.87	0.84	0.71
Non Current Liabilities Total	-0.98	-0.77	-0.91	-0.97	-0.99	0.91	-0.98	-0.65	-0.72	0.3	0.82	-0.51	-0.7	-0.79	-0.64	-0.73	-0.98	0.86	-0.89		-0.68	-0.89	-0.97	1.0	-0.99	-0.68
Capital Lease Obligations	0.7	0.99	0.89	0.67	0.69	-0.87	0.73	1.0	0.41	0.31	-0.88	-0.09	0.2	0.78	0.73	0.97	0.66	-0.63	0.71	-0.68		0.48	0.83	-0.67	0.69	1.0
Other Current Assets	0.93	0.6	0.76	0.91	0.92	-0.78	0.89	0.46	0.83	-0.15	-0.59	0.56	0.46	0.87	0.7	0.54	0.85	-0.75	0.75	-0.89	0.48		0.82	-0.87	0.92	0.5
Other Stockholder Equity	0.96	0.89	0.97	0.94	0.97	-0.95	0.98	0.81	0.65	-0.12	-0.88	0.35	0.59	0.85	0.7	0.87	0.94	-0.84	0.88	-0.97	0.83	0.82		-0.96	0.97	0.83
Total Liab	-0.98	-0.76	-0.89	-0.95	-0.98	0.92	-0.97	-0.65	-0.7	0.31	0.83	-0.48	-0.7	-0.77	-0.63	-0.72	-0.97	0.84	-0.87	1.0	-0.67	-0.87	-0.96		-0.98	-0.67
Net Invested Capital	1.0	0.79	0.89	0.95	1.0	-0.9	0.99	0.66	0.77	-0.19	-0.77	0.46	0.6	0.84	0.71	0.73	0.97	-0.82	0.84	-0.99	0.69	0.92	0.97	-0.98		0.69
Property Plant And Equipment Gross	0.7	0.99	0.89	0.67	0.7	-0.87	0.73	1.0	0.43	0.33	-0.88	-0.09	0.18	0.8	0.76	0.97	0.66	-0.62	0.71	-0.68	1.0	0.5	0.83	-0.67	0.69

Click cells to compare fundamentals

C4 Therapeutics Account Relationship Matchups

C4 Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	118.3M	400.1M	506.8M	430.8M	376.5M	362.8M
Short Long Term Debt Total	13.7M	22.9M	42.9M	87.2M	71.0M	46.2M
Other Current Liab	6.7M	8.5M	12.3M	15.1M	15.4M	11.2M
Total Current Liabilities	33.6M	43.9M	51.2M	44.5M	42.8M	44M
Total Stockholder Equity	(112.0M)	280.8M	389.6M	289.2M	246.1M	185.9M
Other Liab	72.7M	53.6M	24.4M	16.9M	15.2M	14.4M
Net Tangible Assets	(112.0M)	280.8M	389.6M	289.2M	332.6M	168.9M
Property Plant And Equipment Net	18.9M	16.6M	35.1M	77.5M	71.1M	43.9M
Current Deferred Revenue	20.7M	27.6M	31.8M	33.5M	15.5M	27.2M
Net Debt	(76.8M)	(158.8M)	(33.2M)	57.4M	(55.6M)	(58.4M)
Retained Earnings	(117.5M)	(183.8M)	(267.7M)	(395.9M)	(528.4M)	(502.0M)
Accounts Payable	5.4M	5.7M	4.5M	1.2M	1.4M	2.6M
Cash	90.5M	181.7M	76.1M	29.8M	126.6M	99.2M
Non Current Assets Total	21.5M	19.1M	181.1M	143.3M	105.3M	90.4M
Cash And Short Term Investments	90.5M	371.7M	309.3M	337.1M	253.7M	256.4M
Net Receivables	4.6M	4.5M	5.7M	1.5M	11.8M	15.3M
Common Stock Shares Outstanding	43.0M	43.1M	46.0M	48.9M	49.6M	45.0M
Liabilities And Stockholders Equity	118.3M	400.1M	506.8M	430.8M	376.5M	362.8M
Non Current Liabilities Total	196.6M	75.5M	65.9M	97.1M	87.6M	96.7M
Capital Lease Obligations	13.7M	12.9M	32.1M	75.7M	71.0M	40.3M
Other Current Assets	1.6M	9.7M	21.4M	9.9M	5.7M	9.0M
Other Stockholder Equity	(105.5M)	464.6M	658.1M	689.3M	774.6M	435.6M
Total Liab	230.2M	119.3M	117.2M	141.6M	130.3M	128.7M
Net Invested Capital	(112.0M)	290.8M	400.4M	300.7M	246.1M	191.8M
Property Plant And Equipment Gross	18.9M	16.6M	42.0M	85.6M	78.9M	48.1M
Total Current Assets	96.8M	381.0M	325.7M	287.6M	271.2M	272.4M
Accumulated Other Comprehensive Income	(1K)	13K	(775K)	(4.1M)	(127K)	(133.4K)
Net Working Capital	63.1M	337.2M	274.4M	243.0M	228.4M	228.4M
Short Term Debt	880K	2.1M	2.7M	11.7M	10.4M	5.2M
Property Plant Equipment	18.9M	16.6M	3.1M	7.4M	6.7M	10.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether C4 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeutics Stock:

How To Invest In CCCC

Details

Is CCCC Stock a good investment?

Details

What is C4 Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.

You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 Therapeutics. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.71)

Revenue Per Share

0.522

Quarterly Revenue Growth

0.387

Return On Assets

(0.21)

Return On Equity

(0.46)

The market value of C4 Therapeutics is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is C4 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 Therapeutics' market value can be influenced by many factors that don't directly affect C4 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between C4 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

CCCC Deferred Long Term Liab vs Net Debt Analysis

Deferred Long Term Liab vs Net Debt

Deferred Long Term Liab vs Net Debt Correlation Analysis

Correlation Coefficient

Deferred Long Term Liab

Net Debt

C4 Therapeutics fundamental ratios Correlations

C4 Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

C4 Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Capital Lease Obligations	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Liab	+ 1.0	Non Current Liabilities Total

Net Invested Capital	- 0.99	Non Current Liabilities Total
Common Stock Shares Outstanding	- 0.99	Net Receivables
Non Current Liabilities Total	- 0.99	Total Stockholder Equity
Net Invested Capital	- 0.98	Total Liab
Non Current Liabilities Total	- 0.98	Cash And Short Term Investments
Non Current Liabilities Total	- 0.98	Net Tangible Assets